Why it matters: The DEA is set to reveal new rules on synthetic cannabinoids, reflective of recommendations from the US Department of Health and Human Services. They have received multiple petitions and are currently reviewing their guidelines. The new rules could affect the classification of hemp-derived cannabinoids and are expected to appear in the Federal Register later this fall.
What they are saying: The DEA’s Section Chief of Drug and Chemical Evaluation Section, Terrance Boos, presented a PowerPoint presentation at the 2023 Supply Chain Conference in Houston, where he confirmed the agency has received multiple petitions to review their synthetic cannabinoid rules. Boos noted the new rules could change the classification of hemp-derived cannabinoids, though the exact nature of the changes is yet to be publicly revealed.
The big picture: Consistent laws for the hemp-CBD industry remain lacking, with individual states adopting divergent policies when it comes to the legal recognition of hemp-derived cannabinoids, as seen with delta-8 THC. The lack of consistent regulations has allowed data expressing the rise in label tampering and the impact of delta-8 THC products to fuel industry growth.
What to watch: The new rules to be revealed by the DEA will have a widespread implication on the Hemp-CBD industry. Following the unveiling later this year, the public comment period will begin, providing an opportunity for interested parties to request on-the-record hearings.
Give your take: Despite individual state policies set regarding legal recognition of hemp-derived cannabinoids, There currently appears to be a lack of consensus in the hemp-CBD industry regarding the legal framework. Coming up with consistent laws would help both hemp-CBD companies and state-level legislators protect consumers and regulate the industry better.
